- freely available
The Problems of Radiofrequency Ablation as an Approach for Advanced Unresectable Ductal Pancreatic Carcinoma
AbstractAdvanced ductal pancreatic carcinoma (PC) remains a challenge for current surgical and medical approaches. It has recently been claimed that radiofrequency ablation (RFA) may be beneficial for patients with locally advanced or metastatic PC. Using the MEDLINE database, we found seven studies involving 106 patients in which PC was treated using RFA. The PC was mainly located in the pancreatic head (66.9%) with a median size of 4.6 cm. RFA was carried out in 85 patients (80.1%) with locally advanced PC and in 21 (19.9%) with metastatic disease. Palliative surgical procedures were carried out in 41.5% of the patients. The average temperature used was 90 °C (with a temperature range of 30–105 °C) and the ratio between the number of passes of the probe and the size of the tumor in centimeters was 0.5 (range of 0.36–1). The median postoperative morbidity and mortality were 28.3% and 7.5%, respectively; the median survival was 6.5 months (range of 1–33 months). In conclusion, RFA is a feasible technique: however, its safety and long-term results are disappointing; Thus, the RFA procedure should not be recommended in clinical practice for a PC patient.
Share & Cite This Article
Pezzilli, R.; Ricci, C.; Serra, C.; Casadei, R.; Monari, F.; D’Ambra, M.; Corinaldesi, R.; Minni, F. The Problems of Radiofrequency Ablation as an Approach for Advanced Unresectable Ductal Pancreatic Carcinoma. Cancers 2010, 2, 1419-1431.View more citation formats
Pezzilli R, Ricci C, Serra C, Casadei R, Monari F, D’Ambra M, Corinaldesi R, Minni F. The Problems of Radiofrequency Ablation as an Approach for Advanced Unresectable Ductal Pancreatic Carcinoma. Cancers. 2010; 2(3):1419-1431.Chicago/Turabian Style
Pezzilli, Raffaele; Ricci, Claudio; Serra, Carla; Casadei, Riccardo; Monari, Francesco; D’Ambra, Marielda; Corinaldesi, Roberto; Minni, Francesco. 2010. "The Problems of Radiofrequency Ablation as an Approach for Advanced Unresectable Ductal Pancreatic Carcinoma." Cancers 2, no. 3: 1419-1431.